Dermatology

Study to Evaluate the Safety and Efficacy of BF-200 ALA (Ameluz®) and BF-RhodoLED® in the Treatment of Superficial Basal Cell Carcinoma (sBCC) With Photodynamic Therapy (PDT).

Condition:   Superficial Basal Cell Carcinoma
Interventions:   Combination Product: Photodynamic therapy (PDT) (ALA-PDT, Ameluz®-PDT);   Combination Product: Placebo Photodynamic therapy (PDT) (vehicle to BF-200 ALA containing no active ingredient)
Sponsor:   Biofrontera Bioscience GmbH
Recruiting
ClinicalTrials.gov: Dermatology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 29, 2018 / by / in
Bioequivalence Study of Adapalene Gel 0.3% in Subjects With Facial Acne Vulgaris

Condition:   Acne Vulgaris
Interventions:   Drug: Adapalene Gel 0.3%;   Drug: Differin 0.3% Topical Gel;   Drug: Adapalene Gel 0.3% Vehicle Placebo
Sponsors:   Aleor Dermaceuticals Limited;   Catawba Research, LLC
Recruiting
ClinicalTrials.gov: Dermatology | Recruiting, Not yet recruiting, Available Studies | United States | First posted in the last 100 days

September 26, 2018 / by / in